We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Miss
Elizabeth
Page
elizabeth.page@icr.ac.uk
Prof
Ros
Eeles
rosalind.eeles@icr.ac.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prostate cancer (PrCa) is the most common cancer in men in the UK with over 47,000 men diagnosed every year. Research shows the main contributing factors to PrCa development are age, a family history of PrCa, and being from certain ethnic backgrounds. These risk factors can be grouped into environmental and inherited factors (i.e. genetic changes).
The team's previous research shows that defects in certain genes are not only associated with higher rates of PrCa development, but are associated with more aggressive disease. It is likely that it is not simply a family history of PrCa that is linked with this phenomenon, but also the presence of mutations in a persons DNA (genetic material) from birth. Genetic 'panel' tests can detect mutations in known PrCa genes and ‘genetic profiling’ can be used to look at a person's DNA for many common genetic changes involved in PrCa and adding them together to give an overall genetic risk score.
This study is a non-interventional single-site study, at the Royal Marsden Hospital (RMH). It will offer PrCa-specific genetic testing to men with, or at high-risk of, PrCa to identify the prevalence of genetic defects in 2 high-risk cohorts.
1. Men with PrCa AND diagnosed young (ie under 70, OR with a family history, OR with disease that has spread (metastatic).
2. Unaffected men with a family history PrCa defined as:
a. A first degree relative(FDR) diagnosed < 70 years
b. Two FDR/second degree relative(SDR), one diagnosed < 70 years
c. Three FD/SDR diagnosed at any age(on the same side of family)
This study will evaluate the usefulness of this knowledge within a clinical setting to determine how it informs management of these men, in terms of screening and/or treatment. Identifying men with such mutations earlier in their disease trajectory will offer new insights into the role these genes play within PrCa progression and treatment response.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Genetic epidemiology;
You can take part if:
You may not be able to take part if:
WHO performance status 4
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Institute of Cancer Research: Royal Cancer Hospital and funded by CANCER RESEARCH UK; PEACOCK CHARITABLE TRUST; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 40158
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
